Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Keddy

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Scientific Reports|September 27, 2024
Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domainKristen Jones, Clare Keddy, Chelsea Jenkins, et al.
Nature Reviews. Clinical Oncology|August 8, 2020
ROS1-dependent cancers - biology, diagnostics and therapeuticsAlexander Drilon, Chelsea Jenkins, Sudarshan Iyer, et al.
Molecular Cancer Therapeutics|December 15, 2021
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase InhibitorsClare Keddy, Pushkar Shinde, Kristen Jones, et al.
NPJ Precision Oncology|August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology|August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
EMBO Molecular Medicine|August 17, 2023
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSudarshan R Iyer, Kevin Nusser, Kristen Jones, et al.
Cold Spring Harbor Molecular Case Studies|August 25, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusionClare Keddy, Tanaya Neff, Jianya Huan, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scientific Reports|September 27, 2024
Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domainKristen Jones, Clare Keddy, Chelsea Jenkins, et al.
Nature Reviews. Clinical Oncology|August 8, 2020
ROS1-dependent cancers - biology, diagnostics and therapeuticsAlexander Drilon, Chelsea Jenkins, Sudarshan Iyer, et al.
Molecular Cancer Therapeutics|December 15, 2021
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase InhibitorsClare Keddy, Pushkar Shinde, Kristen Jones, et al.
NPJ Precision Oncology|August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology|August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
EMBO Molecular Medicine|August 17, 2023
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSudarshan R Iyer, Kevin Nusser, Kristen Jones, et al.
Cold Spring Harbor Molecular Case Studies|August 25, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusionClare Keddy, Tanaya Neff, Jianya Huan, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 1